ShareCompartir
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Announcements: Amyotrophic Lateral Sclerosis (ALS) Awareness Month — May 2012
May is Amyotrophic Lateral Sclerosis (ALS) Awareness Month. ALS, also known as Lou Gehrig's disease, is a progressive, fatal, neurodegenerative disorder of the upper and lower motor neurons. Persons with ALS usually die within 2–5 years of diagnosis.
In October 2010, the Agency for Toxic Substances and Disease Registry (ATSDR) launched the National ALS Registry to collect, manage, and analyze data regarding persons with ALS. The registry uses information provided by registrants with ALS through a secure Internet portal and existing data from national databases, including the Centers for Medicare and Medicaid Services and the U.S. Department of Veterans Affairs. Through the Internet portal, registrants can participate in brief surveys to provide additional information about their illness and possible risk factors so that researchers can gain a better understanding of ALS.
ATSDR is collaborating with the ALS Association, Muscular Dystrophy Association, and other organizations to make all ALS patients and their families aware of the opportunity to register in the National ALS Registry. When sufficient data have been gathered to provide a representative picture of patients with ALS in the United States, ATSDR will begin analyzing the data and providing deidentified data to other researchers.
In addition, ATSDR is undertaking various initiatives to help strengthen the National ALS Registry. These include using selected state and metropolitan area surveillance activities to help evaluate the registry's completeness, funding a bioregistry feasibility study to link potential specimen data collected (e.g., blood, saliva, and tissue) with existing registry surveys, and developing a system to inform registrants about new research studies and clinical trials. Additional information regarding these initiatives and the National ALS Registry is available at http://www.cdc.gov/als.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
